Be among trailblazing marketing pros at Brandweek this September 23–26 in Phoenix, Arizona. Experience incredible networking, insightful sessions and a boost of inspiration at ADWEEK’s ultimate brand event. Register by May 13 to save 35%.
CHICAGO Independent Cramer-Krasselt has won creative duties on Boehringer Ingelheim Pharmaceutical’s recently acquired Zantac heartburn medication after a review, according to sources.
Estimated billings are $35-40 million.
C-K here will handle traditional and online creative development and media strategy, along with online buying and planning.
An agency representative declined comment. Calls to Boehringer were not immediately returned.
Boehringer Ingelheim in Germany bought Zantac from Pfizer last October for $500 million. The product competes with over-the-counter medications such as Pepcid, Mylanta and Tums, as well as several prescription medications.
WORK SMARTER - LEARN, GROW AND BE INSPIRED.
Subscribe today!
To Read the Full Story Become an Adweek+ Subscriber
Already a member? Sign in